Diagnostic accuracy of a mutation-specific monoclonal antibody (RM8 clone) for BRAF V600e detection by immunohistochemistry in ameloblastomas
DOI:
https://doi.org/10.5327/2525-5711.274Keywords:
Ameloblastoma, Immunohistochemistry, BRAF V600E, Monoclonal Antibodies, RM8 cloneAbstract
Objective: To determine the diagnostic accuracy of IHC using anti-BRAF V600E monoclonal antibody (RM8 clone) compared to Real-Time PCR in the detection of BRAF V600E mutation in FFPE ameloblastoma samples. Methods: This is a diagnostic accuracy study conducted based on the STARD recommendations. The index test was the IHC with anti-BRAF V600E antibody (RM8 clone), while the reference standard was the DNA analysis through castPCR™ mutation detection assays. The target condition was the detection of BRAF V600E mutation. The FFPE ameloblastoma samples were independently submitted to index test and reference standard. Sensitivity and specificity measures, and positive and negative predictive values were calculated. Results: Fifty-four FFPE ameloblastoma samples were included. The sensitivity and specificity of IHC using the RM8 clone compared do Real-Time PCR for the detection of the BRAF V600E mutation in FFPE ameloblastoma samples was 1.00 (95% CI: 0.90 - 1.00) and 0.46 (95% CI: 0.21 - 0.73), respectively, and the diagnostic test accuracy was calculated as 85.18%. Conclusion: IHC using BRAF V600E-specific antibody (RM8 clone) showed extremely high sensitivity, but suboptimal specificity when compared with Real-Time PCR in the detection of BRAF V600E mutation in FPPE ameloblastoma samples.
References
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54. https://doi.org/10.1038/nature00766
Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011;10(3):385-94. https://doi.org/10.1158/1535-7163.MCT-10-0799
World Health Organization. Head and neck tumours. Lyon: International Agency for Research on Cancer; 2022.
Martins-de-Barros AV, Silva CCG, Gonçalves KKN, Almeida RAC, Silva EDO, Araújo FAC, et al. Does BRAF V600E mutation affect recurrence rate of ameloblastomas? Systematic review and meta-analysis. J Oral Pathol Med. 2023;52(8):701-9. https://doi.org/10.1111/jop.13458
Effiom OA, Ogundana OM, Akinshipo AO, Akintoye SO. Ameloblastoma: current etiopathological concepts and management. Oral Dis. 2018;24(3):307-16. https://doi.org/10.1111/odi.12646
Martins-de-Barros AV, Anjos RS, Silva CCG, Silva EDO, Araújo FAC, Carvalho MV. Diagnostic accuracy of immunohistochemistry compared with molecular tests for detection of BRAF V600E mutation in ameloblastomas: systematic review and meta-analysis. J Oral Pathol Med. 2022;51(3):223-30. https://doi.org/10.1111/jop.13278
Loo E, Khalili P, Beuhler K, Siddiqi I, Vasef MA. BRAF V600E mutation across multiple tumor types: correlation between DNA-based sequencing and mutation-specific immunohistochemistry. Appl Immunohistochem Mol Morphol. 2018;26(10):709-13. https://doi.org/10.1097/pai.0000000000000516
Capper D, Preusser M, Schittenhelm J. Characterization of immunohistochemical staining patterns of an antibody specific for BRAF V600E protein in primary and metastatic brain tumors. Clin Neuropathol. 2011;30:254-5.
Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS, et al. Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Cancer Res. 2014;20(21):5517-26. https://doi.org/10.1158/1078-0432.ccr-14-1069
Kurppa KJ, Catón J, Morgan PR, Ristimäki A, Ruhin B, Kellokoski J, et al. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol. 2014;232(5):492-8. https://doi.org/10.1002/path.4317
Heikinheimo K, Huhtala JM, Thiel A, Kurppa KJ, Heikinheimo H, Kovac M, et al. The mutational profile of unicystic ameloblastoma. J Dent Res. 2019;98(1):54-60. https://doi.org/10.1177/0022034518798810
Oh K, Cho SD, Yoon HJ, Lee JI, Ahn SH, Hong SD. High prevalence of BRAF V600E mutations in Korean patients with ameloblastoma: clinicopathological significance and correlation with epithelial‐mesenchymal transition. J Oral Pathol Med. 2019;48(5):413-20. https://doi.org/10.1111/jop.12851
Marcelino BMRS, Parise GK, Canto AM, Sassi LM, Sarmento DJS, Costa ALF, et al. Comparison of immunohistochemistry and DNA sequencing for BRAF V600E mutation detection in mandibular ameloblastomas. Appl Immunohistochem Mol Morphol. 2021;29(5):390-3. https://doi.org/10.1097/PAI.0000000000000904
Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open. 2016;6(11):e012799. https://doi.org/10.1136/bmjopen-2016-012799
Fregnani ER, Perez DEC, Almeida OP, Fonseca FP, Soares FA, Castro-Junior G, et al. BRAF-V600E expression correlates with ameloblastoma aggressiveness. Histopathology. 2017;70(3):473-84. https://doi.org/10.1111/his.13095
Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahring L, Kwei KA, et al. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet. 2014;46(7):722-5. https://doi.org/10.1038/ng.2986
Martins-de-Barros AV, Barros AMI, Lazo RJGS, Barbosa Neto AG, Araújo FAC, Carvalho MV. BRAF V600E mutation detected in cell-free DNA from conventional ameloblastomas fluid aspirate. Oral Dis. 2024;30(6):3962-5. https://doi.org/10.1111/odi.14855
Kaye FJ, Ivey AM, Drane WE, Mendenhall WM, Allan RW. Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst. 2014;107(1):378. https://doi.org/10.1093/jnci/dju378
Tan S, Pollack JR, Kaplan MJ, Colevas AD, West RB. BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(1):e5-7. https://doi.org/10.1016/j.oooo.2015.12.016
Fernandes GS, Girardi DM, Bernardes JPG, Fonseca FP, Fregnani ER. Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation. BMC Cancer. 2018;18(1):887. https://doi.org/10.1186/s12885-018-4802-y
Hirschhorn A, Campino GA, Vered M, Greenberg G, Yacobi R, Yahalom R, et al. Upfront rational therapy in BRAF V600E mutated pediatric ameloblastoma promotes ad integrum mandibular regeneration. J Tissue Eng Regen Med. 2021;15(12):1155-61. https://doi.org/10.1002/term.3254
Pereira NB, Pereira KMA, Coura BP, Diniz MG, Castro WH, Gomes CC, et al. BRAFV600E mutation in the diagnosis of unicystic ameloblastoma. J Oral Pathol Med. 2016;45(10):780-5. https://doi.org/10.1111/jop.12443
Roskoski Jr R. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Pharmacol Res. 2018;135:239-58. https://doi.org/10.1016/j.phrs.2018.08.013
Yakout NM, Abdallah DM, Abdelmonsif DA, Kholosy HM, Talaat IM, Elsakka O. BRAFV600E mutational status assessment in cutaneous melanocytic neoplasms in a group of the Egyptian population. Cancer Cell Int. 2023;23(1):17. https://doi.org/10.1186/s12935-023-02858-1
Chang JYF, Lu PH, Tseng CH, Wang YP, Lee JJ, Chiang CP. Factors affecting the accuracy of anti-BRAF V600E immunohistochemistry results in ameloblastomas. J Oral Pathol Med. 2023;52(4):342-50. https://doi.org/10.1111/jop.13399
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Allan Vinícius Martins-de-Barros, Fábio Andrey da Costa Araújo, Ana Maria Ipólito Barros, Raisa Jordana Geraldine Severino Lazo, Adauto Gomes Barbosa Neto, Helker Albuquerque Macedo da Silva, Maria Tereza Cartaxo Muniz, Stefânia Jeronimo Ferreira, Marianne de Vasconcelos Carvalho
This work is licensed under a Creative Commons Attribution 4.0 International License.
